endpts.com·Jun 4, 2026
Parabilis Medicines, a peptide biotech company led by former Johnson & Johnson R&D head Mathai Mammen, is planning to raise over $413 million in its initial public offering (IPO) on Nasdaq to support its peptide development pipeline.
Parabilis Medicines' planned $413 million IPO to support its peptide pipeline is a significant investment signal in the biotech sector, highlighting the ongoing interest and potential in peptide-based therapies. This move, led by former Johnson & Johnson R&D head Mathai Mammen, suggests a strategic focus on leveraging his expertise to advance the company's offerings, which could be of interest for stakeholders tracking developments in biotech IPOs and peptide therapeutics.